Cannapharmarx annual gross margin
2024
2025
Cannapharmarx's gross margin was −153.06% for fiscal 2025.
View full Cannapharmarx company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −153.06% | +204.80 pp |
| 2024 | 2024-12-31 | −357.86% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −50.12% | +218.09 pp |
| Q1 2026 | 2026-03-31 | −65.26% | +84.63 pp |
| Q4 2025 | 2025-12-31 | −375.89% | +32.71 pp |
| Q3 2025 | 2025-09-30 | −67.01% | +47.08 pp |
| Q2 2025 | 2025-06-30 | −268.22% | +1424.61 pp |
| Q1 2025 | 2025-03-31 | −149.89% | — |
| Q4 2024 | 2024-12-31 | −408.60% | — |
| Q3 2024 | 2024-09-30 | −114.09% | — |
| Q1 2024 · Mar 31 | 2024-03-31 | −1,692.82% | — |
Across the available reported history, Cannapharmarx's gross margin increased from −357.86% to −153.06%, a change of +204.80 percentage points. The latest reported quarter, Q2 2026, shows −50.12%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cannapharmarx filings at SEC.gov ↗